Wirkstoffe Z

Zanubrutinib - BRUKINSA (USA)

According to the NCI website zanubrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival. Check for active clinical trials using this agent. 

 

According to the Company BeiGene website

BRUKINSA IS NOW APPROVED  FOR ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY 

More Information in English:

 
Zoledronat - ZOMETA® sowie Generika

A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity.

Indikationen/Anwendungsmöglichkeiten von Zometa gemäss Compendium®:

  • Zur Behandlung von Patienten mit Knochenmetastasen solider Tumoren und bei multiplem Myelom in Verbindung mit einer antineoplastischen Standardtherapie.
  • Behandlung der malignen Hyperkalzämie (HCM), definiert als albuminkorrigiertes Serum-Kalzium (cCa) >12.0 mg/dl [3.0 mmol/l]

Link zur Fachinformation des Compendium®

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)


selleckchem